BOULOGNE-BILLANCOURT, France, March 30, 2016 -- Vallourec, world leader in premium tubular solutions, announced today that it reached an agreement for an additional revolving credit facility for an amount of €450 million, maturing in February 2020. This facility is subject to a covenant to maintain a gearing ratio of a maximum of 75%, similar to Vallourec's other bank facilities.
The new €450 million credit facility granted to Vallourec SA will become available subject to the closing of Vallourec's contemplated rights issue and a total capital increase (including the rights issue and mandatory convertible bonds reserved for Nippon Steel & Sumitomo Metals Corp and Bpifrance) in an amount approximately equal to the €1 billion previously announced, as well as other customary conditions. The credit facility will be available for general financing purposes of the Group.
Assuming the satisfaction of the conditions to availability of the new facilities, the total committed credit facilities available to Vallourec SA and Vallourec Tubes will increase to €2,240 million from €1,790 million previously.
This agreement was reached with a syndicate of five international core banks: Banco Santander, BNP Paribas, Crédit Agricole Corporate and Investment Bank, Natixis and Société Générale Corporate & Investment Banking, underlining their confidence and support to the Group.
In addition, Vallourec has reached an agreement to extend by three years its existing bilateral revolving credit facility with J.P. Morgan for its US subsidiary Vallourec Star, LP in an amount of $80 million. This facility will become available subject in particular to the same conditions as the Vallourec SA facility relating to the capital increase.
About Vallourec
Vallourec is a world leader in premium tubular solutions primarily serving the energy markets, as well as other industrial applications.
With over 20,000 employees in 2015, integrated manufacturing facilities, advanced R&D and a presence in more than 20 countries, Vallourec offers its customers innovative global solutions to meet the energy challenges of the 21st century.
Listed on Euronext in Paris (ISIN code: FR0000120354, Ticker VK) and eligible for the Deferred Settlement System (SRD), Vallourec is included in the following indices: SBF 120 and Next 150.
In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R2094, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.
| For further information, please contact | ||
|
Investor relations Etienne Bertrand Tel: +33 (0)1 49 09 35 58 [email protected] |
Press relations Héloïse Rothenbühler Tel: +33 (0)1 41 03 77 50 [email protected] |
|
| Follow us on Twitter @Vallourec | ||
PDF version http://hugin.info/143606/R/1998482/736925.pdf
HUG#1998482


Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



